Clinical Trial

PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma

Study acronym: PICSTAT
Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This prospective, single-center pilot study is being performed to find out whether Zr-89 crefmirlimab berdoxam "CD8 PET/CT" scans can improve the effectiveness of the tumor-infiltrating lymphocyte (TIL) therapy called lifileucel ("Study Treatment") in treating metastatic melanoma. Participants must first provide consent to the companion protocol (UPCC 19426, PICSTAT CD8 PET) before being eligible to consent to this protocol.
Trial Details
NCT Number NCT07700121
Lead Sponsor Abramson Cancer Center at Penn Medicine
Collaborators: Iovance Biotherapeutics, Inc.
Conditions Unresectable or Metastatic Melanoma
Enrollment 10 participants
Start Date 2026-10-01
Primary Completion 2028-10-01 (estimated)
Study Completion 2029-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-13